Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure

In order to limit 5-fluorouracil (5-FU) toxicity, some health agencies recommend evaluating dihydropyrimidine dehydrogenase (DPD) deficiency before any 5-FU treatment introduction. In our study, we investigated relationships between 5-FU clearance and markers of DPD activity such as uracilemia (U),...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pharmaceuticals (Basel)
Auteurs principaux: Dolat, Marine, Macaire, Pauline, Goirand, Françoise, Vincent, Julie, Hennequin, Audrey, Palmier, Rémi, Bengrine-Lefevre, Leïla, Ghiringhelli, François, Royer, Bernard, Schmitt, Antonin
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7700344/
https://ncbi.nlm.nih.gov/pubmed/33238487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13110416
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires